Get the Stockscreener App
101.37
0.35%
-0.36
Pre-market:
101.37
Boston Scientific Corp stock is traded at $101.37, with a volume of 5.19M.
It is down -0.35% in the last 24 hours and down -4.40% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
See More
Previous Close:
$101.73
Open:
$101.81
24h Volume:
5.19M
Relative Volume:
0.65
Market Cap:
$147.06B
Revenue:
$17.55B
Net Income/Loss:
$2.03B
P/E Ratio:
73.99
EPS:
1.37
Net Cash Flow:
$2.72B
1W Performance:
+1.98%
1M Performance:
-4.40%
6M Performance:
+15.15%
1Y Performance:
+32.84%
1-Day Range:
$100.84
$102.27
1-Week Range:
$98.00
$102.41
52-Week Range:
$71.88
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
101.37 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
ABT
Abbott Laboratories
|
132.41 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
373.26 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.73 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.98 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
February 2026 Options Now Available For Boston Scientific (BSX) - Nasdaq
Boston Scientific’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings - Investing.com Canada
This Boston Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Boston Scientific (BSX) Receives Outperform Rating from Leerink Partners | BSX Stock News - GuruFocus
Boston Scientific (BSX) Receives Outperform Rating from Analyst | BSX Stock News - GuruFocus
Does This Valuation Of Boston Scientific Corporation (NYSE:BSX) Imply Investors Are Overpaying? - Yahoo Finance
Why the Market Dipped But Boston Scientific (BSX) Gained Today - Yahoo Finance
Boston Scientific Shares Rally Over 1%, Highlighting Strong Long-Term Growth - Daily Chhattisgarh News
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth? - Yahoo Finance
What's the secret behind Boston Sci's successful product launches? - BioWorld MedTech
Implantable Remote Patient Monitoring Devices Market to Grow 21.7% CAGR by 2029 - GlobeNewswire Inc.
Five things: The Newbury GM, Zoominfo cuts, Vertex, Boston Scientific and casino night - The Business Journals
Boston Scientific to sell 24-acre campus in Minnetonka - Finance & Commerce
Boston Scientific is selling a Minnesota campus - MassDevice
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock - The Globe and Mail
Boston Scientific lists 24-acre Minnesota campus for sale ahead of Maple Grove move - The Business Journals
How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks? - MSN
Boston Scientific lists 24-acre Minnetonka campus for sale ahead of Maple Grove move - The Business Journals
Boston Scientific Stock Slips Over 1% Amid Short-Term Pullback - Daily Chhattisgarh News
Boston Scientific (BSX) Upgraded to Buy: Here's Why - Yahoo Finance
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy? - Yahoo Finance
Boston Scientific’s EVP sells $5.8 million in stock By Investing.com - Investing.com Nigeria
Boston Scientific’s EVP sells $5.8 million in stock - Investing.com
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Boston Scientific (NYSE:BSX) Secures US$30-45 Million Deal with Bittium for ECG Devices - Yahoo Finance
Emerging Markets Power Boston Scientific: Will The Growth Trend Continue? - Barchart.com
Here's Why Boston Scientific (BSX) is a Strong Growth Stock - Yahoo Finance
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue? - Yahoo Finance
How Is Boston Scientific's Stock Performance Compared To Other Medical Device Stocks? - Barchart.com
Rising obesity levels spur endoscopic sleeve uptick - BioWorld MedTech
Boston Scientific (BSX): Company Profile, Stock Price, News, Rankings - Fortune
Boston Scientific’s longtime DEI, HR leader exits for chief HR role at new company - MassDevice
Insider Sell: Edward Ludwig Sells 4,000 Shares of Boston Scienti - GuruFocus
Before the Bell-Boston Scientific drops on profit miss - Reuters
Insider Sell: Edward Ludwig Sells 4,000 Shares of Boston Scientific Corp (BSX) - GuruFocus
Piper Sandler maintains Boston Scientific stock at Overweight - Investing.com
Boston Scientific (NYSE:BSX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook - Benzinga
Boston Scientific ends TAVR sales; J&J shares Monarch robot data - MedTech Dive
Boston Scientific (BSX) Ends Acurate TAVR Program, Shifts Focus to Promising Projects | BSX Stock News - GuruFocus
BSX: Analyst Reiterates Buy Rating for Boston Scientific | BSX S - GuruFocus
In TAVR setback, Boston Sci pulls plug on Acurate valves - BioWorld MedTech
Boston Scientific discontinues Acurate TAVR sales, cites regulatory burden - MassDevice
Boston Scientific Ends ACURATE Valve Sales By Investing.com - Investing.com Canada
Evercore ISI maintains Boston Scientific stock at Outperform - Investing.com
TD Cowen maintains Boston Scientific stock at $115 target By Investing.com - Investing.com South Africa
TD Cowen maintains Boston Scientific stock at $115 target - Investing.com
Boston Scientific (BSX) Discontinues Sales of ACURATE Aortic Valve Systems - GuruFocus
Boston Scientific (BSX) Discontinues Valve Product Amid Regulato - GuruFocus
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Boston Scientific Corp Stock (BSX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology |
Jun 04 '25 |
Sale |
102.88 |
56,372 |
5,799,630 |
178,342 |
0.03%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):